Oncogenic synergism between ErbB1, nucleolin, and mutant ras

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2140-2151

  Farin, Keren ^a   Schokoroy, Sari ^a   Haklai, Roni ^a   Cohen Or, Ifat ^a   Elad Sfadia, Galit ^a   Reyes Reyes, Merit E ^b   Bates, Paula J ^b   Cox, Adrienne D ^c   Kloog, Yoel ^a   Pinkas Kramarski, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEOLIN; ONCOPROTEIN; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MUTANT PROTEINS; MUTATION; NEOPLASMS, EXPERIMENTAL; PHOSPHOPROTEINS; PROTEIN BINDING; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA-BINDING PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 79952745983     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2887     Document Type: Article

References (48)

1. Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. Monogr Natl Cancer Inst 1992;1992:181-7.
2. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ II. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 2009;122:1-8.
3. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
4. Lemmon MA. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009;315:638-48.
5. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, et al. Oncogenes and signal transduction. Cell 1991;64:281-302.
6. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
7. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kD glycoprotein that induces differentiation of mammary tumor cells. Cell 1992;69:205-16.
8. Normanno N, Ciardiello F. EGF-related peptides in the pathophysiology of the mammary gland. J Mammary Gland Biol Neoplasia 1997;2:143-51. (Pubitemid 127716443)
9. Tal-Or P, Erlich S, Porat-Shliom N, Goldshmit Y, Ben-Baruch G, Shaharabani E, et al. Ligand-independent regulation of ErbB4 receptor phosphorylation by activated Ras. J Cell Biochem 2006;98:1482-94. (Pubitemid 44141853)
10. Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, et al. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 1992;65:271-4.
11. Di Segni A, Ben-Baruch N, Pinkas-Kramarski R. The ErbB family of receptor tyrosine kinases: key regulators in breast cancer and other malignancies. In: Ben-Baruch A, editor. Breast Cancer: From Pathogenesis to Potential Therapeutic Modalities. Kerala, India: Transworld Research Network; 2009. p. 77-105.
12. Di Segni A, Farin K, Pinkas-Kramarski R. Identification of nucleolin as new ErbB receptors-interacting protein. PLoS One 2008;3:e2310:1-9.
13. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999;274:26369-77.
14. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999;13:1911-22. (Pubitemid 29517621)
15. Storck S, Thiry M, Bouvet P. Conditional knockout of nucleolin in DT40 cells reveals the functional redundancy of its RNA binding domains. Biol Cell 2009;101:153-6.
16. Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol 2007;8:66:1-16.
17. Legrand D, Vigie K, Said E, Elass E, Masson M, Slomianny M, et al. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 2004;271:303-17. (Pubitemid 38130458)
18. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S, et al. Nuclear translocation of urokinase-type plasminogen activator. Blood 2008;112:100-10.
19. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, et al. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One 2008;3:e2518.
20. Teng Y, Girvan AC, Casson LK, Pierce WM Jr, Qian M, Thomas SD, et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 2007;67:10491-500. (Pubitemid 350070825)
21. Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001;276:43221-30.
22. Bates PJ, Choi EW, Nayak LV. G-rich oligonucleotides for cancer treatment. Methods Mol Biol 2009;542:379-92.
23. Aifa S, Aydin J, Nordvall G, Lundstrom I, Svensson SP, Hermanson O. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. Exp Cell Res 2005;302:108-14. (Pubitemid 39482372)
24. Farin K, Di Segni A, Mor A, Pinkas-Kramarski R. Structure-function analysis of nucleolin and ErbB receptors interactions. PLoS One 2009;4:e6128:1-12.
25. Rotblat B, Niv H, Andre S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1 (L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res 2004;64:3112-8. (Pubitemid 38581411)
26. Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, et al. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A. 1999;96:14019-24.
27. Niv H, Gutman O, Kloog Y, Henis YI. Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. J Cell Biol 2002;157:865-72. (Pubitemid 34847823)
28. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, Bégin LR, et al. Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 2006;12:2730-7.
29. Diskin T, Tal-Or P, Erlich S, Mizrachy L, Alexandrovich A, Shohami E, et al. Closed head injury induces upregulation of Beclin 1 at the cortical site of injury. J Neurotrauma 2005;22:750-62. (Pubitemid 40995307)
30. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2008;61:89-96. (Pubitemid 47512630)
31. Mongelard F, Bouvet P. Nucleolin: a multiFACeTed protein. Trends Cell Biol 2007;17:80-6. (Pubitemid 46199181)
32. Birchenall-Roberts MC, Fu T, Kim SG, Huang YK, Dambach M, Resau JH, et al. K-Ras4B proteins are expressed in the nucleolus: interaction with nucleolin. Biochem Biophys Res Commun 2006;348:540-9. (Pubitemid 44209152)
33. Paz A, Haklai R, Elad G, Ballan E, Kloog Y. Galectin-1 binds H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2000;20:7486-93. (Pubitemid 33086908)
34. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments KRas activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004;279:34922-30. (Pubitemid 39318128)
35. Belanis L, Plowman SJ, Rotblat B, Hancock JF, Kloog Y. Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol Biol Cell 2008;19:1404-14. (Pubitemid 351805095)
36. Shalom-Feuerstein R, Plowman SJ, Rotblat B, Ariotti N, Tian T, Hancock JF, et al. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res 2008;68:6608-16.
37. Plowman SJ, Muncke C, Parton RG, Hancock JF. H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. Proc Natl Acad Sci USA 2005;102:15500-5. (Pubitemid 41528086)
38. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003;4:373-84. (Pubitemid 36565569)
39. Kloog Y, Cox AD. Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. Semin Cancer Biol 2004;14:253-61. (Pubitemid 38824586)
40. Philips MR. Compartmentalized signalling of Ras. Biochem Soc Trans 2005;33:657-61. (Pubitemid 41160832)
41. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
42. Harding AS, Hancock JF. Using plasma membrane nanoclusters to build better signaling circuits. Trends Cell Biol 2008;18:364-71.
43. Inder KL, Lau C, Loo D, Chaudhary N, Goodall A, Martin S, et al. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction. J Biol Chem 2009;284:28410-9.
44. Storck S, Shukla M, Dimitrov S, Bouvet P. Functions of the histone chaperone nucleolin in diseases. Subcell Biochem 2007;41:125-44.
45. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
46. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 2008;3:31-47. (Pubitemid 351223208)
47. Eng C. K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. Clin Adv Hematol Oncol 2008;6:174-5. (Pubitemid 351516204)
48. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009;100:1704-19.